Table of Contents
EAST WINDSOR, N.J. – Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application nitrofurantoin oral suspension USP, 25 mg/5 mL. Aurobindo Pharma’s nitrofurantoin oral suspension, are an AB-rated generic equivalent to the reference listed drug (RLD), Furadantin Oral Suspension USP, manufactured by Casper Pharma .
Nitrofurantoin oral suspension, are indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci, Staphylococcus aureus, and certain susceptible strains of Klebsiella and Enterobacter species.
Nitrofurantoin oral suspension, has an estimated market size of US $55 million for the twelve months ending March 2023, as per IQVIA.
